INTRODUCTION

Benzoyl peroxide (BPO) is recommended for treatment of acne of all severities. 1 It is bactericidal against C. acnes and within hair follicles with no risk of development of resistance. 2,3 and also has mild keratolytic effects. 4 BPO is widely used as a therapeutic agent in many different vehicles and as combination therapy with other medications. 3,4 Multiple analyses have indicated that the efficacy of BPO is enhanced when used in combination with topical retinoids, such as tretinoin. 3,4 However, BPO usually causes degradation of tretinoin, reducing its effectiveness. 4

METHODS

Two multicenter, randomized, double-blind, parallel-group vehicle-controlled trials (SGT-65-04 and SGT-65-05) carried out at 63 sites across the United States (Figure 1). A microencapsulated benzoyl peroxide (E-BPO) and microencapsulated tretinoin (E-ATRA) cream was formulated by adapting and improving Sol-Gel Technologies’ advanced drug delivery technology platform. This technology enables sustained delivery of active pharmaceutical ingredients, reduces potential irritation caused by direct application of the drugs to the skin, and extends drug delivery time, while being able to interact with and explore these data more intimately, please click here: https://www.solgelposters.com

RESULTS

Achievement of IGA Success

The efficacy of E-BPO/E-ATRA in pediatric and adolescent patients (9-17 years of age) was at least equivalent to that for the entire population.

Reduction in Inflammatory Lesions

The efficacy of E-BPO/E-ATRA in pediatric and adolescent patients (9-17 years of age) was at least equivalent to that for the entire population.

Reduction in Non-Inflammatory Lesions

The efficacy of E-BPO/E-ATRA in pediatric and adolescent patients (9-17 years of age) was at least equivalent to that for the entire population.

ACKNOWLEDGMENTS

The authors wish to recognize the support of Robert Rholes, PhD, and Thomas Purdy, CNP, of AraMed Strategies, LLC, for their editorial and scientific analysis support. Their assistance was funded along with the studies represented herein, by Sol-Gel Technologies, Ltd. The use of Sol-Gel’s microparticulate technology platform provides a stable combination of BPO and tretinoin, extending drug delivery time, and reducing potential irritation caused by direct application of the drugs to the skin.

REFERENCES